Financial Wire

Telix Enters Attractive Market With Late-Stage Brain Cancer Drug Trial in US, Jefferies Says

-- Telix (ASX:TLX) entered a potentially attractive market after the commencement of phase three trial for recurrent glioblastoma, a type of brain cancer, in the US, Jefferies said in a note on Wednesday.

The investment firm said that with around 20,000 patients diagnosed annually in the US with recurrent glioblastoma and limited treatment options, the market appears promising for its drug candidate TLX101-Tx.

Jefferies, however, gave a risk-weighted valuation to the experimental drug in Telix's overall valuation.

The brokerage boosted Telix's fiscal year 2026 net profit after tax estimate to $5.1 million from $3.3 million, driven by the inclusion of TLX101-Tx in its valuation, with first sales expected in fiscal year 2029, refinancing of $600 million in convertible bonds, and changes to assumptions for expenses and costs.

Jefferies kept a buy rating on Telix and raised its price target to AU$27.40 from AU$24.30.

Related Articles

Asia

Market Chatter: Hybe Shares Slip 3% as Police Seek to Arrest Founder over 2020 IPO Probe

Shares of Hybe (KRX:352820) fell nearly 3% to 2,48,000 won in Tuesday morning trade after the Seoul Metropolitan Police Agency sought to arrest the entertainment giant's founder Bang Si-hyuk on charges of misleading early investors before the company's initial public offering in 2020.Bang has also been accused of concealing profit-sharing arrangements tied to a private equity fund, Bloomberg reported Tuesday.Authorities suspect Bang made about 190 billion won in illicit gains. Bang denies any wrongdoing, according to the report.The probe, referred to by the Financial Services Commission last year, has raised concerns related to governance, it said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$KRX:352820
Asia

Eswin Materials Tech's 2025 Loss Widens; Shares Down 4%

Xi'an Eswin Materials Technology's (SHA:688783) net loss attributable to shareholders in 2025 slightly widened year on year to 738.2 million yuan, or 0.21 yuan per share, according to the company's annual report published Tuesday on the Shanghai bourse.The attributable loss a year earlier was 737.6 million yuan, while earnings per share were unchanged from 0.21 yuan a year earlier.Operating revenue climbed 25% to 2.65 billion yuan from 2.12 billion yuan in the previous year.The Chinese semiconductor company's shares dropped 4% during the morning trade.

$SHA:688783
Asia

ISOTeam Secures Contract Worth SG$30 Million; Shares Up 4%

ISOTeam (SGX:5WF) secured SG$30 million worth of contracts, according to a Monday filing with the Singapore Exchange.Shares of the facilities maintenance company were up nearly 4% in Tuesday trading.The contracts include a SG$8.3 million coating and painting projects contract, addition and alteration projects worth SG$6.8 million, repair and redecoration contracts worth SG$5.1 million, electrical work projects worth SG$4.8 million and landscaping projects worth SG$1.4 million.Following the award, the company's current order book stands at around SG$186.5 million.

$SGX:5WF